前列腺癌患者血清PSA表达情况及PCNA表达的相关性研究
|
摘要
目的:探讨前列腺癌患者血清PSA表达情况及PCNA表达的关系。方法:选取邛崃市医疗中心医院2013年8月至2017年8月期间行手术切除治疗的前列腺癌患者58例为研究对象,同时选取同期手术治疗的前列腺良性增生患者30例作为对照研究。采用微粒子酶免分析法检测患者血清PSA表达情况,采用免疫组化学染色法检测患者癌组织中PCNA表达情况,探讨PSA及PCNA的表达与患者临床病理特征的关系及两者的相关性。结果:PSA与PCNA在前列腺癌组与前列腺良性增生组中的表达均具有显著差异,比较结果具有统计学意义(P <0. 05); PSA在中低组织分化程度及临床分期C期中的表达水平高于高组织分化程度及临床分期为A/B中,比较结果均具有统计学意义(all P <0. 05),PSA表达水平在不同年龄及淋巴结转移情况中比较无统计学意义(P> 0. 05); PCNA在中组织低分化程度以及发生淋巴结转移的癌组织中表达水平显著高于高组织分化程度及未发生淋巴结转移的癌组织中,比较结果均具有统计学意义(all P <0. 05),PCNA在不同年龄及临床分期中的表达情况比较无统计学意义,比较结果均具有统计学意义(all P> 0. 05); PSA与PCNA的表达呈现正相关性(r=0. 236,P=0. 008)。结论:PSA与PCNA的表达与前列腺癌进展程度有关,临床可通过检测患者血清PSA及癌组织中PCNA的表达情况,为患者病情的诊断及预后提高一定的指导依据。
Objective: To investigate the expression of serum PSA in patients with prostate cancer and its correlation with the expression of PCNA. Methods: 58 patients with prostate cancer and 30 patients with benign prostatic hyperplasia treated in Qionglai Medical Center Hospital from August 2013 to August 2017 were selected.Microparticle enzyme immunoassay was used to detect the expression of serum PSA,and the expression of PCNA in the cancer tissues was detected by immunohistochemical staining. The relationship between the expression of PSA and PCNA and the clinicopathological features of the patients and the correlation between themwas studied. Results:Difference in the expression of PSA and PCNA between the prostate cancer group and the benign prostatic hyperplasia group was statistically significant( P < 0. 05). The expression level of PSA in tissue of middle and lowdifferentiation degree and clinical C stage was higher than that in tissue of high differentiation and clinical A/Bstage( all P <0. 05). Difference in the expression level of PSA was not statistically significant betweenpatients of different age and lymph node metastasis( P > 0. 05). The expression level of PCNA in the tissue of low degree of differentiation and cancer tissue withlymph node metastasis was significantly higher than that in tissue of high degree of differentiation and cancer tissue without lymph node metastasis( all P < 0. 05). Difference in expression of PCNA between patients of different age and clinical staging was not statistically significant( all P > 0. 05). The expression of PSA and PCNA was positively correlated( r = 0. 236,P = 0. 008). Conclusions: The expression of PSA and PCNA is related to the progression of prostate cancer. The diagnosis and prognosis of the patient's condition can be improved by detecting the serum PSA and the expression of PCNA in the cancer tissue.
Objective: To investigate the expression of serum PSA in patients with prostate cancer and its correlation with the expression of PCNA. Methods: 58 patients with prostate cancer and 30 patients with benign prostatic hyperplasia treated in Qionglai Medical Center Hospital from August 2013 to August 2017 were selected.Microparticle enzyme immunoassay was used to detect the expression of serum PSA,and the expression of PCNA in the cancer tissues was detected by immunohistochemical staining. The relationship between the expression of PSA and PCNA and the clinicopathological features of the patients and the correlation between themwas studied. Results:Difference in the expression of PSA and PCNA between the prostate cancer group and the benign prostatic hyperplasia group was statistically significant( P < 0. 05). The expression level of PSA in tissue of middle and lowdifferentiation degree and clinical C stage was higher than that in tissue of high differentiation and clinical A/Bstage( all P <0. 05). Difference in the expression level of PSA was not statistically significant betweenpatients of different age and lymph node metastasis( P > 0. 05). The expression level of PCNA in the tissue of low degree of differentiation and cancer tissue withlymph node metastasis was significantly higher than that in tissue of high degree of differentiation and cancer tissue without lymph node metastasis( all P < 0. 05). Difference in expression of PCNA between patients of different age and clinical staging was not statistically significant( all P > 0. 05). The expression of PSA and PCNA was positively correlated( r = 0. 236,P = 0. 008). Conclusions: The expression of PSA and PCNA is related to the progression of prostate cancer. The diagnosis and prognosis of the patient's condition can be improved by detecting the serum PSA and the expression of PCNA in the cancer tissue.
引文
[1] Hatakeyama S,Yoneyama T,Tobisawa Y,et al. Recent progress and perspectives on prostate cancer biomarkers. International Journal of Clinical Oncology,2017,22(2):214-214.
[2]逄琳,陈新,王艳. F-PSA/T-PSA联合MRI在前列腺癌诊断中的应用价值.实用癌症杂志,2016,31(4):635-637.
[3] Carvalho MI,Pires I,Prada J,et al. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands:Prognostic Impact by a Multivariate Survival Analysis. Veterinary Pathology,2016,53(6):1138-1138.
[4] MartíJ,Santacruz MC,Serra R,et al. Systematic differences in time of cerebellar-neuron origin derived from bromodeoxyuridine immunoperoxidase staining protocols and tritiated thymidine autoradiography:A comparative study. International Journal of Developmental Neuroscience,2015,47(4):216-228.
[5]曾翔,梁勇,付光庆. IGF-1、PCNA和Caspase3在前列腺癌组织的表达及临床意义.海南医学,2013,24(19):2809-2812.
[6]孙杨,王绍平. PSA、PSAD、F-PSA/PSA在前列腺癌诊断中的价值分析.中国实验诊断学,2016,20(01):113-114.
[7]张红双,李杨亮,陆佳.急性前列腺炎患者血清前列腺特异性抗原的变化及其意义.蚌埠医学院学报,2014,39(5):627-629.
[8] Stege RH,Tribukait B,Carlstr9m KAM,et al. Tissue PSA from fine‐needle biopsies of prostatic carcinoma as related to serum PSA,clinical stage,cytological grade,and DNA ploidy. Prostate,2015,38(3):183-188.
[9]金秋龙,郭建锋,郑凯,等.血清PSA含量及前列腺PSA密度与经直肠超声引导下前列腺穿刺活检诊断前列腺癌的关系.中国介入影像与治疗学,2015,12(10):616-620.
[10]杨渝,邵志强,郭嘉祥.前列腺癌肿瘤组织恶性分子表达与血清PSA、XAGE-1b、Spondin-2含量的相关性分析.海南医学院学报,2015,21(12):1693-1696.
[11] Vykhovanets E,Shankar E,Shukla S,et al. Abstract 91:NF-κB as a prognostic marker and therapeutic target in prostate cancer. Cancer Research,2015,75(15):91-91.
[12]王超. DHA对雌雄激素诱导大鼠前列腺增生防治作用的实验研究.天津:南开大学,2015.
[13] Mu Y,Xie C,Kiang MY,et al. Targeting of cytosolic phospholipase A2 impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget,2015,6(33):34458-34474.
[14]黄霞,刘景丽,吴健松,等.分化型甲状腺癌中雌激素受体、孕激素受体和增殖细胞核抗原的表达及临床意义.疑难病杂志,2015,14(6):586-589.
[15]秦桂萍,华玉兰,侯海娜.前列腺癌组织p504S和p63与血清PSA表达水平相关性分析.中华肿瘤防治杂志,2013,20(3):200-202.
[2]逄琳,陈新,王艳. F-PSA/T-PSA联合MRI在前列腺癌诊断中的应用价值.实用癌症杂志,2016,31(4):635-637.
[3] Carvalho MI,Pires I,Prada J,et al. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands:Prognostic Impact by a Multivariate Survival Analysis. Veterinary Pathology,2016,53(6):1138-1138.
[4] MartíJ,Santacruz MC,Serra R,et al. Systematic differences in time of cerebellar-neuron origin derived from bromodeoxyuridine immunoperoxidase staining protocols and tritiated thymidine autoradiography:A comparative study. International Journal of Developmental Neuroscience,2015,47(4):216-228.
[5]曾翔,梁勇,付光庆. IGF-1、PCNA和Caspase3在前列腺癌组织的表达及临床意义.海南医学,2013,24(19):2809-2812.
[6]孙杨,王绍平. PSA、PSAD、F-PSA/PSA在前列腺癌诊断中的价值分析.中国实验诊断学,2016,20(01):113-114.
[7]张红双,李杨亮,陆佳.急性前列腺炎患者血清前列腺特异性抗原的变化及其意义.蚌埠医学院学报,2014,39(5):627-629.
[8] Stege RH,Tribukait B,Carlstr9m KAM,et al. Tissue PSA from fine‐needle biopsies of prostatic carcinoma as related to serum PSA,clinical stage,cytological grade,and DNA ploidy. Prostate,2015,38(3):183-188.
[9]金秋龙,郭建锋,郑凯,等.血清PSA含量及前列腺PSA密度与经直肠超声引导下前列腺穿刺活检诊断前列腺癌的关系.中国介入影像与治疗学,2015,12(10):616-620.
[10]杨渝,邵志强,郭嘉祥.前列腺癌肿瘤组织恶性分子表达与血清PSA、XAGE-1b、Spondin-2含量的相关性分析.海南医学院学报,2015,21(12):1693-1696.
[11] Vykhovanets E,Shankar E,Shukla S,et al. Abstract 91:NF-κB as a prognostic marker and therapeutic target in prostate cancer. Cancer Research,2015,75(15):91-91.
[12]王超. DHA对雌雄激素诱导大鼠前列腺增生防治作用的实验研究.天津:南开大学,2015.
[13] Mu Y,Xie C,Kiang MY,et al. Targeting of cytosolic phospholipase A2 impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget,2015,6(33):34458-34474.
[14]黄霞,刘景丽,吴健松,等.分化型甲状腺癌中雌激素受体、孕激素受体和增殖细胞核抗原的表达及临床意义.疑难病杂志,2015,14(6):586-589.
[15]秦桂萍,华玉兰,侯海娜.前列腺癌组织p504S和p63与血清PSA表达水平相关性分析.中华肿瘤防治杂志,2013,20(3):200-202.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |